Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1995 2
1996 1
1997 1
1998 3
1999 6
2000 2
2001 1
2003 1
2004 1
2006 5
2007 5
2008 5
2009 9
2010 11
2011 14
2012 12
2013 4
2014 14
2015 15
2016 23
2017 13
2018 17
2019 10
2020 20
2021 17
2022 24
2023 21
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

228 results

Results by year

Filters applied: . Clear all
Page 1
Multiple sclerosis progression: time for a new mechanism-driven framework.
Kuhlmann T, Moccia M, Coetzee T, Cohen JA, Correale J, Graves J, Marrie RA, Montalban X, Yong VW, Thompson AJ, Reich DS; International Advisory Committee on Clinical Trials in Multiple Sclerosis. Kuhlmann T, et al. Lancet Neurol. 2023 Jan;22(1):78-88. doi: 10.1016/S1474-4422(22)00289-7. Epub 2022 Nov 18. Lancet Neurol. 2023. PMID: 36410373 Free PMC article. Review.
Multiple sclerosis, a treatable disease.
Doshi A, Chataway J. Doshi A, et al. Among authors: chataway j. Clin Med (Lond). 2016 Dec;16(Suppl 6):s53-s59. doi: 10.7861/clinmedicine.16-6-s53. Clin Med (Lond). 2016. PMID: 27956442 Free PMC article. Review.
Secondary Progressive Multiple Sclerosis: New Insights.
Cree BAC, Arnold DL, Chataway J, Chitnis T, Fox RJ, Pozo Ramajo A, Murphy N, Lassmann H. Cree BAC, et al. Among authors: chataway j. Neurology. 2021 Aug 24;97(8):378-388. doi: 10.1212/WNL.0000000000012323. Epub 2021 Jun 4. Neurology. 2021. PMID: 34088878 Free PMC article. Review.
Secondary Progressive Multiple Sclerosis: A Review of Clinical Characteristics, Definition, Prognostic Tools, and Disease-Modifying Therapies.
Ziemssen T, Bhan V, Chataway J, Chitnis T, Campbell Cree BA, Havrdova EK, Kappos L, Labauge P, Miller A, Nakahara J, Oreja-Guevara C, Palace J, Singer B, Trojano M, Patil A, Rauser B, Hach T. Ziemssen T, et al. Among authors: chataway j. Neurol Neuroimmunol Neuroinflamm. 2022 Nov 22;10(1):e200064. doi: 10.1212/NXI.0000000000200064. Print 2023 Jan. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36414428 Free PMC article. Review.
Practical approach to the diagnosis of adult-onset leukodystrophies: an updated guide in the genomic era.
Lynch DS, Wade C, Paiva ARB, John N, Kinsella JA, Merwick Á, Ahmed RM, Warren JD, Mummery CJ, Schott JM, Fox NC, Houlden H, Adams ME, Davagnanam I, Murphy E, Chataway J. Lynch DS, et al. Among authors: chataway j. J Neurol Neurosurg Psychiatry. 2019 May;90(5):543-554. doi: 10.1136/jnnp-2018-319481. Epub 2018 Nov 22. J Neurol Neurosurg Psychiatry. 2019. PMID: 30467211 Free PMC article. Review.
Cognitive rehabilitation and aerobic exercise for cognitive impairment in people with progressive multiple sclerosis (CogEx): a randomised, blinded, sham-controlled trial.
Feinstein A, Amato MP, Brichetto G, Chataway J, Chiaravalloti ND, Cutter G, Dalgas U, DeLuca J, Farrell R, Feys P, Filippi M, Freeman J, Inglese M, Meza C, Motl RW, Rocca MA, Sandroff BM, Salter A; CogEx Research Team. Feinstein A, et al. Among authors: chataway j. Lancet Neurol. 2023 Oct;22(10):912-924. doi: 10.1016/S1474-4422(23)00280-6. Lancet Neurol. 2023. PMID: 37739574 Free article. Clinical Trial.
Multiple sclerosis.
Nicholas R, Chataway J. Nicholas R, et al. Among authors: chataway j. BMJ Clin Evid. 2009 May 14;2009:1202. BMJ Clin Evid. 2009. PMID: 21733201 Free PMC article. Review.
Multiple sclerosis.
Nicholas R, Chataway J. Nicholas R, et al. Among authors: chataway j. BMJ Clin Evid. 2007 Aug 15;2007:1202. BMJ Clin Evid. 2007. PMID: 19454107 Review.
The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.
IST-3 collaborative group; Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, Murray G, Innes K, Venables G, Czlonkowska A, Kobayashi A, Ricci S, Murray V, Berge E, Slot KB, Hankey GJ, Correia M, Peeters A, Matz K, Lyrer P, Gubitz G, Phillips SJ, Arauz A. IST-3 collaborative group, et al. Lancet. 2012 Jun 23;379(9834):2352-63. doi: 10.1016/S0140-6736(12)60768-5. Epub 2012 May 23. Lancet. 2012. PMID: 22632908 Free PMC article. Clinical Trial.
228 results